MABTHERA
RITUXIMAB
Public price
13.737,00 MAD
Reimbursement base
13.737,00 MAD
Active substance
RITUXIMAB
Reimbursable
What is this medicine?
A CD20-directed cytolytic antibody and biosimilar to rituximab.
Verified summary
RITUXIMAB, SOLUTION A DILUER POUR PERFUSION, 500 MG, 1 FLACON 50 ML
Common uses
Treatment of Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), moderately-to-severely-active Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and moderate to severe Pemphigus Vulgaris (PV).
Class
CD20-directed cytolytic antibody
Availability note
Reimbursable
Hospital price
13.475,00 MAD
Strength
500 MG
Form
SOLUTION A DILUER POUR PERFUSION
Presentation
1 FLACON 50 ML
Type
P
Therapeutic class
ANTINEOPLASIQUE CYTOTOXIQUE
This information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.
Price history
Reference price recorded since 2017-12-18: 13.737,00 MAD
Available presentations and strengths
MABTHERA
100 MG / 10 ML · BOITE DE 2 FLACON DE 10 ML
4,21 MAD
MABTHERA
500 MG / 50 ML · BOITE DE 1 FLACON DE 50 ML
9,73 MAD
MABTHERA
1400 MG / 11,7 ML · BOITE D'UN FLACON DE 15 ML
16,78 MAD
MABTHERA
1600 MG / 13,4 ML · BOITE D'UN FLACON DE 20 ML
18,15 MAD
MABTHERA 100 MG / 10 ML
100 MG / 10 ML · 2 flacons de 10 ml
4.208,00 MAD
MABTHERA
100 MG · 2 FLACON 10 ML
5.842,00 MAD
MABTHERA 500 MG / 50 ML
500 MG / 50 ML · 1 flacon de 50 ml
9.735,00 MAD
MABTHERA 1400 MG / 11.7 ML
1400 MG / 11.7 ML · Flacon de 15 ml
16.778,00 MAD